Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147))

Christopher G. Willett, Yves Boucher, Emmanuelle Di Tomaso, Dan G. Duda, Lance L. Munn, Ricky T. Tong, Daniel C. Chung, Dushyant V. Sahani, Sanjeeva P. Kalva, Sergey V. Kozin, Mari Mino, Kenneth S. Cohen, David T. Scadden, Alan C. Hartford, Alan J. Fischman, Jeffrey W. Clark, David P. Ryan, Andrew X. Zhu, Lawrence S. Blaszkowsky, Helen X. ChenPaul C. Shellito, Gregory Y. Lauwers, Rakesh K. Jain

Research output: Contribution to journalComment/debatepeer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Erratum: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer (Nature Medicine (2004) 10 (145-147))'. Together they form a unique fingerprint.